ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2013, 'PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.', Journal of Clinical Oncology, 31, pp. TPS5614 - TPS5614, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps5614
,2013, 'Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).', Journal of Clinical Oncology, 31, pp. LBA5503 - LBA5503, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.lba5503
,2013, 'The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).', Journal of Clinical Oncology, 31, pp. 9602 - 9602, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9602
,2013, 'Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study', Gynecologic Oncology, 129, pp. 310 - 317, http://dx.doi.org/10.1016/j.ygyno.2013.02.007
,2013, 'Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer', Nature Communications, 4, http://dx.doi.org/10.1038/ncomms2629
,2013, 'Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31', Nature Communications, 4, http://dx.doi.org/10.1038/ncomms2613
,2013, 'Obesity and risk of ovarian cancer subtypes: Evidence from the Ovarian Cancer Association Consortium', Endocrine-Related Cancer, 20, pp. 251 - 262, http://dx.doi.org/10.1530/ERC-12-0395
,2013, 'Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis', EUROPEAN JOURNAL OF NUTRITION, 52, pp. 705 - 715, http://dx.doi.org/10.1007/s00394-012-0376-7
,2013, 'High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival', PLoS ONE, 8, http://dx.doi.org/10.1371/journal.pone.0054356
,2013, 'A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer', Annals of Oncology, 24, pp. 937 - 943, http://dx.doi.org/10.1093/annonc/mds538
,2013, 'Chemotherapy-induced peripheral neurotoxicity: A critical analysis', CA Cancer Journal for Clinicians, 63, pp. 419 - 437, http://dx.doi.org/10.3322/caac.21204
,2013, 'Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk', PLoS Genetics, 9, http://dx.doi.org/10.1371/journal.pgen.1003212
,2013, 'Patient-reported outcomes in ovarian cancer clinical trials', Annals of Oncology, 24, http://dx.doi.org/10.1093/annonc/mdt474
,2013, 'Primary surgical management with tailored adjuvant radiation for stage IB2 cervical cancer', Obstetrics and Gynecology, 121, pp. 765 - 772, http://dx.doi.org/10.1097/AOG.0b013e3182887836
,2013, 'A fibroid or cancer? A rare case of mixed choriocarcinoma and epithelioid trophoblastic tumour.', Case Rep Obstet Gynecol, 2013, pp. 492754, http://dx.doi.org/10.1155/2013/492754
,2013, 'Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing', Oncology Nursing Forum, 40, pp. 275 - 283, http://dx.doi.org/10.1188/13.ONF.40-03AP
,2013, 'The acceptability, feasibility and efficacy (Phase I/II study) of the OVERcome (Olive oil, Vaginal Exercise and moisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer.', Journal of Sexual Medicine, EPUB ahead of print, pp. 2549 - 2558, http://dx.doi.org/10.1111/jsm.12156
,2013, 'Using decision aids for improving treatment-choices for women with breast cancer.', Breast Cancer Management, 2, pp. 23 - 31, http://dx.doi.org/10.2217/bmt.12.61
,2012, 'The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia', Investigative Ophthalmology and Visual Science, 53, pp. 7889 - 7895, http://dx.doi.org/10.1167/iovs.12-10765
,2012, 'BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group', Journal of Clinical Oncology, 30, pp. 2654 - 2663, http://dx.doi.org/10.1200/JCO.2011.39.8545
,2012, 'Breast cancer risk and 6q22.33: Combined results from breast cancer association consortium and consortium of investigators on modifiers of brca1/2', PLoS ONE, 7, http://dx.doi.org/10.1371/journal.pone.0035706
,2012, 'A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL.', Journal of Clinical Oncology, 30, pp. TPS5116 - TPS5116, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps5116
,2012, 'Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and U.K. phase I/II trials.', Journal of Clinical Oncology, 30, pp. 4531 - 4531, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4531
,2012, 'Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.', Journal of Clinical Oncology, 30, pp. 5001 - 5001, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5001
,2012, 'Predictors of resilience in women treated for breast cancer: A prospective study.', Journal of Clinical Oncology, 30, pp. 9044 - 9044, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9044
,2012, 'Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).', Journal of Clinical Oncology, 30, pp. 5081 - 5081, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5081
,2012, 'Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.', Journal of Clinical Oncology, 30, pp. 3048 - 3048, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3048
,2012, 'Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study.', Journal of Clinical Oncology, 30, pp. 5022 - 5022, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5022
,2012, 'Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer', BRITISH JOURNAL OF CANCER, 106, pp. 1618 - 1625, http://dx.doi.org/10.1038/bjc.2012.156
,2012, 'Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer', New England Journal of Medicine, 366, pp. 1382 - 1392, http://dx.doi.org/10.1056/NEJMoa1105535
,2012, 'Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer', Journal of Clinical Oncology, 30, pp. 372 - 379, http://dx.doi.org/10.1200/JCO.2011.36.9215
,2012, 'Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: An international prospective breast cancer family registry population-based cohort study', Journal of Clinical Oncology, 30, pp. 19 - 26, http://dx.doi.org/10.1200/JCO.2010.33.0068
,2012, 'Cancer of the ovary, fallopian tube, and peritoneum', International Journal of Gynecology and Obstetrics, 119, http://dx.doi.org/10.1016/S0020-7292(12)60025-3
,2012, 'Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers', Hereditary Cancer in Clinical Practice, 10, pp. A11 - A11, http://dx.doi.org/10.1186/1897-4287-10-s2-a11
,2012, 'Cancer-related fatigue in women with breast cancer: outcomes of a 5 year prospective cohort study.', Journal of Clinical Oncology, 30, pp. 1805 - 1812, http://dx.doi.org/10.1200/JCO.2011.34.6148
,2012, 'How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer', BMC Cancer, 12, pp. 320, http://dx.doi.org/10.1186/1471-2407-12-320
,2012, 'LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin', Cancer Research, 72, pp. 4060 - 4073, http://dx.doi.org/10.1158/0008-5472.CAN-12-0203
,2012, 'Pathological diagnosis of ovarian cancer', Hereditary Cancer in Clinical Practice, 10, pp. A82 - A82, http://dx.doi.org/10.1186/1897-4287-10-s2-a82
,2011, 'A Phase 3 Trial of Bevacizumab in Ovarian Cancer', NEW ENGLAND JOURNAL OF MEDICINE, 365, pp. 2484 - 2496, http://dx.doi.org/10.1056/NEJMoa1103799
,2011, 'Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up', LANCET ONCOLOGY, 12, pp. 1101 - 1108, http://dx.doi.org/10.1016/S1470-2045(11)70270-4
,2011, 'The role of hormonal therapy in gynecological cancers - Current status and future directions', International Journal of Gynecological Cancer, 21, pp. 1328 - 1333, http://dx.doi.org/10.1097/IGC.0b013e31821d6021
,2011, 'International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial', JOURNAL OF CLINICAL ONCOLOGY, 29, pp. 2171 - 2177, http://dx.doi.org/10.1200/JCO.2010.32.3139
,2011, 'Accelerated BEP for advanced germ cell tumors: An Australian multicenter phase I/II trial.', JOURNAL OF CLINICAL ONCOLOGY, 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4561
,2011, 'Cancer-related fatigue and sexual functioning in women with early breast cancer: Is there a link?', J Clin Oncol, 29, pp. 9072, http://www.ncbi.nlm.nih.gov/pubmed/28021533
,2011, 'OVERcome: An intervention study to improve sexual function in women with breast cancer.', J Clin Oncol, 29, pp. 9066, http://www.ncbi.nlm.nih.gov/pubmed/28021576
,2011, 'Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers', PLoS ONE, 6, http://dx.doi.org/10.1371/journal.pone.0018064
,2011, 'A response to the forgotten fallopian tube', Nature Reviews Cancer, 11, http://dx.doi.org/10.1038/nrc2946-c2
,2011, 'Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer', BREAST CANCER RESEARCH, 13, http://dx.doi.org/10.1186/bcr2837
,2011, 'A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer', Breast Cancer Research and Treatment, 129, pp. 467 - 476, http://dx.doi.org/10.1007/s10549-011-1471-9
,2011, 'A specialist breast care nurse role for women with metastatic breast cancer: Enhancing supportive care', Oncology Nursing Forum, 38, pp. 627 - 631
,